Arthritis News and Research

Latest Arthritis News and Research

GSK obtains exclusive license to ChemoCentryx's CCX354 CCR1 inhibitor for RA

ChemoCentryx, Inc., today announced that GlaxoSmithKline (GSK) has exercised its option to obtain an exclusive license for further development and worldwide commercialization of the investigational medicine CCX354, a potent and selective inhibitor of CCR1, a chemokine receptor that drives the recruitment of inflammatory cells into the joints of patients with rheumatoid arthritis (RA).

6 Jan 2012

Rilonacept appears safe and well-tolerated in patients with gout

A phase II clinical trial found that rilonacept, an inhibitor of the protein interleukin-1 (IL-1), significantly reduced acute gout flares that occur when initiating uric acid-lowering therapy. Results of the trial—the first placebo-controlled study investigating IL-1 targeted therapy in prevention of gout flares—show rilonacept to be generally well tolerated with no serious infections or treatment-related serious adverse events reported.

5 Jan 2012

Osiris provides update on Prochymal Phase 2 trial for type 1 diabetes

Osiris Therapeutics, Inc., today provided an update on its Phase 2 trial evaluating Prochymal, a formulation of adult mesenchymal stem cells (MSCs), in patients with newly diagnosed type 1 diabetes.

4 Jan 2012

Regeneron, Genentech enter non-exclusive license and partial settlement agreement for EYLEA

Regeneron Pharmaceuticals, Inc. today announced that the Company has entered into a non-exclusive license and partial settlement agreement with Genentech, Inc., a member of the Roche Group relating to U.S. ophthalmic sales of EYLEA (aflibercept) Injection.

3 Jan 2012

Ampio completes enrollment phase of Australian Ampion In Knee trials

Ampio Pharmaceuticals, Inc., a company that discovers and develops new uses for previously approved drugs and new molecular entities, today announced that it is has completed the expanded patient enrollment phase of its Ampion In Knee (AIK) trials in Australia.

3 Jan 2012

FDA invites Amgen for ODAC meeting on XGEVA sBLA to treat castration-resistant prostate cancer

Amgen today announced the U.S. Food and Drug Administration has invited the Company to participate in a meeting of the Oncologic Drugs Advisory Committee (ODAC) on Feb. 8, 2012 to discuss the supplemental Biologics License Application (sBLA) for XGEVA (denosumab) to treat men with castration-resistant prostate cancer (CRPC) at high risk of developing bone metastases.

30 Dec 2011

CEL-SCI to expand Multikine Phase III trial in head and neck cancer

CEL-SCI Corporation is in the process of expanding its Phase III clinical trial of the investigational therapy Multikine (Leukocyte Interleukin, Injection) to 4 additional European countries - Spain, Czech Republic, Slovakia and Croatia.

27 Dec 2011

Synthetic drugs treat Crohn's disease in mice

A team of Weizmann Institute scientists has turned the tables on an autoimmune disease. In such diseases, including Crohn's and rheumatoid arthritis, the immune system mistakenly attacks the body's tissues. But the scientists managed to trick the immune systems of mice into targeting one of the body's players in autoimmune processes, an enzyme known as MMP9.

26 Dec 2011

Pfizer, Karo Bio partner to develop RORgamma modulators for autoimmune diseases

Karo Bio AB has entered into a research collaboration agreement with Pfizer Inc., to discover and develop novel small molecule RORgamma modulators for the treatment of autoimmune diseases.

26 Dec 2011

CEL-SCI reports net loss of $26.8M for fiscal year ended September 30, 2011

CEL-SCI Corporation reported financial results today for the fiscal year ended September 30, 2011.

26 Dec 2011

Graphitic carbon plays key role as lubricating layer on metal-on-metal hip implants

A team of engineers and physicians have made a surprising discovery that offers a target for designing new materials for hip implants that are less susceptible to the joint's normal wear and tear.

23 Dec 2011

Lexicon completes rights offering

Lexicon Pharmaceuticals, Inc. announced today that it has completed its previously announced rights offering pursuant to an effective shelf registration statement.

23 Dec 2011

Surprising finding about implants used in hip replacement surgery

A new study, bringing together an interdisciplinary team of physicians and engineers from the United States and Germany, made a surprising finding about implants used in hip replacement surgery: Graphite carbon is a key element in the lubricating layer that forms on metal-on-metal hip implants. The lubricant has more in common with the lubrication of a combustion engine than that of a natural joint.

23 Dec 2011

Denali Concrete Management initiates enrollment in CF101 phase 3 study for Dry Eye Syndrome

Denali Concrete Management Inc. announced today that it has commenced patient enrollment for a phase 3 clinical study of the safety and efficacy of CF101, daily administered orally, in patients with moderate-to-severe Dry Eye Syndrome.

21 Dec 2011

Despite improvements, disparities in diagnosis and treatment of depression remain

Despite improvements to diagnostic tools and therapies in the two last decades, significant disparities in the diagnosis and treatment of depression remain, according to Rutgers research published online by the American Journal of Public Health; print, February 2012.

21 Dec 2011

UCB initiates EXXELERATE study in rheumatoid arthritis

UCB today announced the start of the EXXELERATE study which will evaluate the short- and long-term efficacy of Cimzia (certolizumab pegol) plus methotrexate (MTX) compared with that of Humira(adalimumab) plus MTX in the treatment of moderate to severe rheumatoid arthritis (RA). The start of this study confirms previously announced plans.

21 Dec 2011

FDA accepts Pfizer's tofacitinib NDA for review

Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for tofacitinib (development code CP-690,550), an investigational novel, oral JAK inhibitor being studied for the treatment of adult patients with moderately to severely active rheumatoid arthritis.

21 Dec 2011

Scientists discover missing link between body's biological clock and sugar metabolism system

Scientists have discovered a missing link between the body's biological clock and sugar metabolism system, a finding that may help avoid the serious side effects of drugs used for treating asthma, allergies and arthritis.

20 Dec 2011

Exactech commences clinical trial to evaluate new cartilage repair technology

Exactech, Inc., a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials announced today it has initiated a prospective, randomized, multi-center, clinical trial to evaluate the safety and effectiveness of a new cartilage repair technology.

19 Dec 2011

Study finds knee pain patterns vary among women over a 12-year period

New research shows 63% of women age 50 and older reported persistent, incident, or intermittent knee pain during a 12-year study period. Predictors for persistent pain included higher body mass index (BMI), previous knee injury, and radiographic osteoarthritis.

19 Dec 2011

Arthritis News and Research

Latest Arthritis News and Research

GSK obtains exclusive license to ChemoCentryx's CCX354 CCR1 inhibitor for RA

Rilonacept appears safe and well-tolerated in patients with gout

Osiris provides update on Prochymal Phase 2 trial for type 1 diabetes

Regeneron, Genentech enter non-exclusive license and partial settlement agreement for EYLEA

Ampio completes enrollment phase of Australian Ampion In Knee trials

FDA invites Amgen for ODAC meeting on XGEVA sBLA to treat castration-resistant prostate cancer

CEL-SCI to expand Multikine Phase III trial in head and neck cancer

Synthetic drugs treat Crohn's disease in mice

Pfizer, Karo Bio partner to develop RORgamma modulators for autoimmune diseases

CEL-SCI reports net loss of $26.8M for fiscal year ended September 30, 2011

Graphitic carbon plays key role as lubricating layer on metal-on-metal hip implants

Lexicon completes rights offering

Surprising finding about implants used in hip replacement surgery

Denali Concrete Management initiates enrollment in CF101 phase 3 study for Dry Eye Syndrome

Despite improvements, disparities in diagnosis and treatment of depression remain

UCB initiates EXXELERATE study in rheumatoid arthritis

FDA accepts Pfizer's tofacitinib NDA for review

Scientists discover missing link between body's biological clock and sugar metabolism system

Exactech commences clinical trial to evaluate new cartilage repair technology

Study finds knee pain patterns vary among women over a 12-year period

Exploring the role of confocal-based high-content imaging in advancing core facilities

Transforming Cardiovascular Care: Insights from Mina Makar at AstraZeneca

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Arthritis News and Research

Latest Arthritis News and Research

Exploring the role of confocal-based high-content imaging in advancing core facilities

Transforming Cardiovascular Care: Insights from Mina Makar at AstraZeneca

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Newsletters you may be interested in